OIA response: Pembrolizumab and nivolumab data

Response to request for information on pembrolizumab and nivolumab.

1 August 2019

[name and contact address redacted]

Dear [name redacted]

REQUEST FOR INFORMATION

Thank you for your request dated 11 July 2019 under the Official Information Act 1982 (OIA) for information relating to pembrolizumab and nivolumab Special Authority data.  Your request was:

Just wondering if this data for Feb and March is yet available?  In addition I would like to request the same data for April, May and June.

The tables below set out the data you requested.

Pembrolizumab

Month submitted

Initial Applications

Initial

Approvals

Renewal Applications

Renewal Approvals

Total applications

Total approvals

Feb 2019

37

30

41

37

78

67

Mar 2019

29

24

49

43

78

67

Apr 2019

35

31

62

50

97

81

May 2019

38

30

57

50

95

80

Jun 2019

38

35

58

42

96

77

Nivolumab

Month submitted

Initial Applications

Initial Approvals

Renewal Applications

Renewal Approvals

Total applications

Total approvals

Feb 2019

<10

<10

<10

<10

<10

<10

Mar 2019

0

0

<10

<10

<10

<10

Apr 2019

0

0

<10

<10

<10

<10

May 2019

<10

<10

<10

0

<10

<10

Jun 2019

0

0

<10

<10

<10

<10

We trust that this information answers your queries.  We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website.  Please get in touch with us if you have any questions about this.

Yours sincerely

Alison Hill
Director, Engagement and Implementation